Mihai-Calin Pavel

Dr. Mihai-Calin Pavel

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 March 2022 in Systematic Reviews
Verified
Journal Article
Open access
PDF file
MPMihai-Calin Pavel
Mihai-Calin Pavel
MBMar Achalandabaso Boira
Mar Achalandabaso Boira
YBYasir Bashir
Yasir Bashir
RMRobert Memba
Robert Memba
ELErik Llácer
Erik Llácer
RJRosa Jorba-Martin
Rosa Jorba-Martin
Background: Laparoscopic cholecystectomy has become the standard surgical approach in the treatment of cholelithiasis. Diverse surgical techniques and different imaging modalities have been described to evaluate the biliary anatomy and prevent or early detect bile duct injuries. X-ray intraoperative cholangiography (IOC) and near infrared indocyanine green fluorescent cholangiography (NIR-ICG) are safe and feasible techniques to assess biliary anatomy. The aim of this systematic review will be to evaluate if NIR-ICG can visualize extrahepatic biliary anatomy more efficiently and safer than IOC in minimally invasive cholecystectomy for gallstone disease. Methods: Literature search will be performed via MEDLINE (PubMed), Embase, Scopus, the Cochrane Central Register of Controlled Trials, and Web of Science Core Collection from 2009 to present. All randomized controlled clinical trials and prospective non-randomized controlled trials which report on comparison of NIR-ICG versus IOC will be included. All patients over 18 years old who require elective or urgent minimally invasive cholecystectomy (undergoing NIR-ICG during this procedure) due to gallstone disease both acute and chronic will be included. Since BDI has a low incidence, the primary outcome will be the ability to visualize extrahepatic biliary anatomy and the time to obtain relevant images of these structures. Two researchers will individually screen the identified records, according to a list of inclusion and exclusion criteria. Bias of the studies will be evaluated with the Newcastle-Ottawa score for non-randomized studies and with The Cochrane Risk of Bias Tool for randomized controlled trials. Quality of evidence for all outcomes will be determined with the GRADE system. The data will be registered in a predesigned database. If selected studies are sufficiently homogeneous, we will perform a meta-analysis of reported results. In the event of a substantial heterogeneity, a narrative synthesis will be provided. Subgroup analysis will be used to investigate possible sources of heterogeneity. Discussion: Understanding the benefits of this technique is critical to ensuring policymakers can make informed decisions as to where preventive efforts should be focused regarding specific imaging techniques. If ICG is proven to be faster and non-invasive, its routine use could be encouraged. Systematic review registration: PROSPERO CRD42020177991.

1 March 2019 in Journal of Surgical Research
Verified
Journal Article
Closed access
MPMihai-Calin Pavel
Mihai-Calin Pavel
ERErnest Reyner
Ernest Reyner
VMVictor Molina
Victor Molina
RGRocio Garcia
Rocio Garcia
ARAngel Ruiz
Angel Ruiz
JGJuan Carlos Garcia-Valdecasas
Juan Carlos Garcia-Valdecasas

1 October 2018 in Cirugía Española
Verified
Journal Article
Closed access
MPMihai-Calin Pavel
Mihai-Calin Pavel
ERErnest Reyner
Ernest Reyner
JFJosep Fuster
Josep Fuster
JGJuan Carlos Garcia-Valdecasas
Juan Carlos Garcia-Valdecasas

1 October 2015 in Cirugía Española
Verified
Journal Article
Closed access
MPMihai-Calin Pavel
Mihai-Calin Pavel
CCConstantino Fondevila Campo
Constantino Fondevila Campo
DMDavid Calatayud Mizrahi
David Calatayud Mizrahi
JFJoana Ferrer
Joana Ferrer
SCSantiago Sanchez Cabús
Santiago Sanchez Cabús
JSJuan Carlos Garcia-Valdecasas Salgado
Juan Carlos Garcia-Valdecasas Salgado


4 December 2020 in Systematic Reviews
Verified
Journal Article
Open access
PDF file
MPMihai-Calin Pavel
Mihai-Calin Pavel
RCRaquel Casanova
Raquel Casanova
LELaia Estalella
Laia Estalella
RMRobert Memba
Robert Memba
ELErik Llàcer-Millán
Erik Llàcer-Millán
RJRosa Jorba
Rosa Jorba
Introduction: Liver resection (LR) in patients with liver metastasis from colorectal cancer remains the only curative treatment. Perioperative chemotherapy improves prognosis of these patients. However, there are concerns regarding the effect of preoperative chemotherapy on liver regeneration, which is a key event in avoiding liver failure after LR. The primary objective of this systematic review is to assess the effect of neoadjuvant chemotherapy on liver regeneration after (LR) or portal vein embolization (PVE) in patients with liver metastasis from colorectal cancer. The secondary objectives are to evaluate the impact of the type of chemotherapy, number of cycles, and time between end of treatment and procedure (LR or PVE) and to investigate whether there is an association between degree of hypertrophy and postoperative liver failure.Methods: This meta-analysis will include studies reporting liver regeneration rates in patients submitted to LR or PVE. Pubmed, Scopus, Web of Science, Embase, and Cochrane databases will be searched. Only studies comparing neoadjuvant vs no chemotherapy, or comparing chemotherapy characteristics (bevacizumab administration, number of cycles, and time from finishing chemotherapy until intervention), will be included. We will select studies from 1990 to present. Two researchers will individually screen the identified records, according to a list of inclusion and exclusion criteria. Primary outcome will be future liver remnant regeneration rate. Bias of the studies will be evaluated with the ROBINS-I tool, and quality of evidence for all outcomes will be determined with the GRADE system. The data will be registered in a predesigned database. If selected studies are sufficiently homogeneous, we will perform a meta-analysis of reported results. In the event of a substantial heterogeneity, a qualitative systematic review will be performed.Discussion: The results of this systematic review may help to better identify the patients affected by liver metastasis that could present low regeneration rates after neoadjuvant chemotherapy. These patients are at risk to develop liver failure after extended hepatectomies and therefore are not good candidates for such aggressive procedures.Systematic review registration: PROSPERO registration number:CRD42020178481(July 5, 2020).